KYSE-30

Derived from a well-differentiated invasive esophageal squamous cell carcinoma resected from a 64-year-old Asian male prior to treatment, KYSE-30 is a prototypic human ESCC line established via initial heterotransplantation in athymic mice. Its extensively characterized genomic landscape and stable phenotype position it as a cornerstone model for dissecting ESCC pathogenesis and therapeutic response.

KYSE-30 harbors a pathogenic TP53 splice-site mutation (intron 6) alongside CDKN2A and HRAS mutations, coupled with high-level co-amplification of MYC, ERBB2 (c-ERB B), and CCND1. This combinatorial genotype faithfully recapitulates the core oncogenic circuitry prevalent in human ESCC.

Genomic profiling reveals that cell cycle gene mutations occur at low frequency across ESCC lines; KYSE-30 is one of only two lines (with TE-1) exhibiting this distinct mutational class. This exclusivity renders it indispensable for studying G1/S checkpoint abrogation and CDK inhibitor sensitivity in an ESCC-relevant context.

KYSE-30 expresses an exceptionally high level of epidermal growth factor receptor, providing a calibrated system for interrogating EGFR-dependent signaling, tyrosine kinase inhibitor efficacy, and receptor-targeted therapeutic strategies.

The line is heterotransplantable in nude mice, enabling in vivo efficacy studies. Engineered derivatives, including GFP-reporter stable lines, support high-content drug screening and real-time tumor tracking in preclinical models.